COMMUNIQUÉS West-GlobeNewswire

Montreal hosts the 4th International Symposium on Arthrogryposis Multiplex Congenita (AMC)

28/09/2024 - 14:30

MONTREAL, Sept. 28, 2024 (GLOBE NEWSWIRE) -- From September 28 to October 1, the Shriners Hospitals for Children - Canada will host the 4 th International Symposium on Arthrogryposis . Organized in collaboration with [...]

SOGC Calls for Vigilance and Continued Advocacy on International Safe Abortion Day

28/09/2024 - 13:00

OTTAWA, Ontario, Sept. 28, 2024 (GLOBE NEWSWIRE) -- As the world observes International Safe Abortion Day, the Society of Obstetricians and Gynaecologists of Canada (SOGC) is reaffirming its unwavering commitment to [...]

La SOGC lance un appel à la vigilance et à la poursuite des représentations pour protéger les droits des femmes à l'occasion de la Journée internationale de l'avortement sécuritaire

28/09/2024 - 13:00

OTTAWA, Ontario, 28 sept. 2024 (GLOBE NEWSWIRE) -- Alors que le monde entier observe la Journée internationale de l'avortement sécuritaire, la Société des obstétriciens et gynécologues du Canada (SOGC) réaffirme son [...]

Natural Alternatives International, Inc. Announces Fiscal 2024 Q4 and YTD Results

28/09/2024 - 01:20

CARLSBAD, Calif., Sept. 27, 2024 (GLOBE NEWSWIRE) -- Natural Alternatives International, Inc. ("NAI") (Nasdaq: NAII), a leading formulator, manufacturer, and marketer of customized nutritional supplements, today [...]

BridgeBio Shares Recurrent Event Analysis of ATTRibute-CM, Demonstrating a 42% Reduction by Acoramidis on the Composite Endpoint of All-Cause Mortality and Recurrent Cardiovascular-related Hospitalization Events

28/09/2024 - 00:00

- Acoramidis treatment led to a highly significant reduction in all-cause mortality (ACM) and recurrent cardiovascular-related hospitalizations (CVH) at Month 30 compared with placebo - Additionally, results from a [...]

Daxor Corporation Streamlines Regulatory Strategy for Groundbreaking Diagnostic Device

27/09/2024 - 23:00

Company to Focus on 510(k) Approval Path, Accelerating Time-to-Market Oak Ridge, TN, Sept. 27, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ: DXR), the global leader in blood volume measurement technology, today [...]

CARVYKTI® ▼ (ciltacabtagene autoleucel; cilta-cel) is the first cell therapy to significantly extend overall survival versus standard therapies for patients with multiple myeloma as early as second line

27/09/2024 - 22:35

45 percent reduction in risk of death achieved with cilta-cel versus standard therapies after three-year follow-up in landmark CARTITUDE-4 study 1 Data featured in a late-breaking oral presentation at the 2024 [...]

CARVYKTI® is the First and Only Cell Therapy to Significantly Extend Overall Survival Compared to Standard of Care in Patients with Multiple Myeloma as Early as Second Line

27/09/2024 - 22:35

Landmark CARTITUDE-4 study results show CARVYKTI ® reduced the risk of death by 45 percent after three-year follow-up Late-breaking data featured in an oral presentation at the 21 st International Myeloma Society Annual [...]

DREAM Pivotal Study Data Presented at the International Surgical Sleep Society 2024 Educational Update

27/09/2024 - 22:30

DREAM Pivotal Study Data Presented at the International Surgical Sleep Society 2024 Educational Update Additional clinical data on patients suffering from Obstructive Sleep Apnea (OSA) demonstrate a clinically [...]

Les Données de l'Étude Pivot DREAM Présentées lors de l'International Surgical Sleep Society 2024 Educational Update

27/09/2024 - 22:30

Les Données de l'Étude Pivot DREAM Présentées lors de l'International Surgical Sleep Society 2024 Educational Update Des données cliniques supplémentaires sur des patients souffrant d'apnée obstructive du sommeil (AOS) [...]

PetMed Express, Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

27/09/2024 - 22:17

DELRAY BEACH, Fla., Sept. 27, 2024 (GLOBE NEWSWIRE) -- PetMed Express, Inc. , dba PetMeds and parent company of PetCareRx, (Nasdaq: PETS), today announced that on September 27, 2024, PetMeds granted two equity awards [...]

PacBio Grants Equity Incentive Award to New Employee

27/09/2024 - 22:05

MENLO PARK, Calif., Sept. 27, 2024 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading provider of high-quality, highly accurate sequencing platforms, today announced that the Compensation Committee of the Company’s [...]

Neurona Therapeutics Announces Participation in Upcoming Investor Conferences in October

27/09/2024 - 20:00

SAN FRANCISCO, Sept. 27, 2024 (GLOBE NEWSWIRE) -- Neurona Therapeutics , a clinical-stage biotherapeutics company advancing regenerative cell therapies for disorders of the nervous system, today announced that Cory R. [...]

DARZALEX® (daratumumab) subcutaneous (SC) formulation-based quadruplet regimen significantly improves minimal residual disease negativity for newly diagnosed multiple myeloma patients for whom transplant is not planned

27/09/2024 - 19:05

Study demonstrates a minimal residual disease (MRD)-negativity rate of 60.9 percent and 43 percent reduction in the risk of progression or death 1 Phase 3 CEPHEUS study results presented in late-breaking oral [...]

Communities Across the Commonwealth Come Together to Celebrate Massachusetts Good Neighbor Day of Action

27/09/2024 - 18:15

-- A broad range of inspiring events including a “Find Your People” fair, intergenerational dinners, a town scavenger hunt, free YMCA admission, and others help people and communities connect-- BOSTON, Sept. 27, 2024 ( [...]

Cytokinetics Presents Additional Data from SEQUOIA-HCM at the HCMS Scientific Sessions

27/09/2024 - 17:00

SOUTH SAN FRANCISCO, Calif., Sept. 27, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that additional data from SEQUOIA-HCM ( S afety, E fficacy, and Q uantitative U nderstanding of O [...]

Dupixent® (dupilumab) Approved in the U.S. as the First-ever Biologic Medicine for Patients with COPD

27/09/2024 - 15:35

Dupixent is indicated for the approximately 300,000 adults in the U.S. with inadequately controlled chronic obstructive pulmonary disease (COPD) and an eosinophilic phenotype Following recent approvals in the EU and [...]

Press Release: Dupixent approved in the US as the first-ever biologic medicine for patients with COPD

27/09/2024 - 15:35

Dupixent approved in the US as the first-ever biologic medicine for patients with COPD Dupixent is indicated for the approximately 300,000 adults in the US with inadequately controlled COPD and an eosinophilic phenotype [...]

Communiqué de presse : Dupixent est le premier médicament biologique approuvé aux États-Unis pour le traitement de la BPCO

27/09/2024 - 15:35

Dupixent est le premier médicament biologique approuvé aux États-Unis pour le traitement de la BPCO Dupixent est indiqué à environ 300 000 adultes aux États-Unis présentant une BPCO inadéquatement contrôlée et un [...]